Expert Interview
A Third View: Looking into the phase 1 data on Intellia Therapeutics' NTLA-2002 in patients with hereditary angioedema.
Ticker(s): NTLAInstitution: University of Pennsylvania
- manages 800 patients with Type 1 allergic reactions
- anaphylactic shock from an allergic reaction
- Familiar with the data for AQST-109
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
